Article
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma.
JCO precision oncology - 1 Mar 2023
Marinoff Amanda E, Spurr Liam F, Fong Christina, Li Yvonne Y, Forrest Suzanne J, Ward Abigail, Doan Duong, Corson Laura, Mauguen Audrey, Pinto Navin, Maese Luke, Colace Susan, Macy Margaret E, Kim AeRang, Sabnis Amit J, Applebaum Mark A, Laetsch Theodore W, Glade-Bender Julia, Weiser Daniel A, Anderson Megan, Crompton Brian D, Meyers Paul, Zehir Ahmet, MacConaill Laura, Lindeman Neal, Nowak Jonathan A, Ladanyi Marc, Church Alanna J, Cherniack Andrew D, Shukla Neerav, Janeway Katherine A
Abstract excerpt
PURPOSE: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic features, and has not facilitated treatment advances. We report on the genomic features of advanced osteosarcoma and provide evidence that genomic alterations can be used for risk stratification....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.